vs
Side-by-side financial comparison of Medpace Holdings, Inc. (MEDP) and SouthState Bank Corp (SSB). Click either name above to swap in a different company.
Medpace Holdings, Inc. is the larger business by last-quarter revenue ($708.5M vs $661.7M, roughly 1.1× SouthState Bank Corp). SouthState Bank Corp runs the higher net margin — 34.1% vs 19.1%, a 15.1% gap on every dollar of revenue. Over the past eight quarters, SouthState Bank Corp's revenue compounded faster (37.4% CAGR vs 17.7%).
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
SouthState Bank, based in Winter Haven, Florida, is an American bank and a subsidiary of SouthState Corporation, a bank holding company. As of May 26, 2025, the company had 371 branches in South Carolina, North Carolina, Georgia, Florida, Alabama, Virginia, Colorado and Texas.
MEDP vs SSB — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $708.5M | $661.7M |
| Net Profit | $135.1M | $225.8M |
| Gross Margin | — | — |
| Operating Margin | 21.6% | 15.1% |
| Net Margin | 19.1% | 34.1% |
| Revenue YoY | 32.0% | — |
| Net Profit YoY | 15.5% | 153.5% |
| EPS (diluted) | $4.65 | $2.28 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $661.7M | ||
| Q4 25 | $708.5M | $581.1M | ||
| Q3 25 | $659.9M | $599.7M | ||
| Q2 25 | $603.3M | $577.9M | ||
| Q1 25 | $558.6M | $544.5M | ||
| Q4 24 | $536.6M | $369.8M | ||
| Q3 24 | $533.3M | $351.5M | ||
| Q2 24 | $528.1M | $350.3M |
| Q1 26 | — | $225.8M | ||
| Q4 25 | $135.1M | $247.7M | ||
| Q3 25 | $111.1M | $246.6M | ||
| Q2 25 | $90.3M | $215.2M | ||
| Q1 25 | $114.6M | $89.1M | ||
| Q4 24 | $117.0M | $144.2M | ||
| Q3 24 | $96.4M | $143.2M | ||
| Q2 24 | $88.4M | $132.4M |
| Q1 26 | — | 15.1% | ||
| Q4 25 | 21.6% | 54.3% | ||
| Q3 25 | 21.5% | 53.6% | ||
| Q2 25 | 20.9% | 48.8% | ||
| Q1 25 | 20.3% | 22.3% | ||
| Q4 24 | 23.4% | 50.7% | ||
| Q3 24 | 21.1% | 53.1% | ||
| Q2 24 | 19.9% | 49.3% |
| Q1 26 | — | 34.1% | ||
| Q4 25 | 19.1% | 42.6% | ||
| Q3 25 | 16.8% | 41.1% | ||
| Q2 25 | 15.0% | 37.2% | ||
| Q1 25 | 20.5% | 16.4% | ||
| Q4 24 | 21.8% | 39.0% | ||
| Q3 24 | 18.1% | 40.7% | ||
| Q2 24 | 16.7% | 37.8% |
| Q1 26 | — | $2.28 | ||
| Q4 25 | $4.65 | $2.47 | ||
| Q3 25 | $3.86 | $2.42 | ||
| Q2 25 | $3.10 | $2.11 | ||
| Q1 25 | $3.67 | $0.87 | ||
| Q4 24 | $3.67 | $1.88 | ||
| Q3 24 | $3.01 | $1.86 | ||
| Q2 24 | $2.75 | $1.73 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $497.0M | $2.9B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $459.1M | $9.0B |
| Total Assets | $2.0B | $68.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $2.9B | ||
| Q4 25 | $497.0M | — | ||
| Q3 25 | $285.4M | — | ||
| Q2 25 | $46.3M | — | ||
| Q1 25 | $441.4M | — | ||
| Q4 24 | $669.4M | — | ||
| Q3 24 | $656.9M | — | ||
| Q2 24 | $510.9M | — |
| Q1 26 | — | $9.0B | ||
| Q4 25 | $459.1M | $9.1B | ||
| Q3 25 | $293.6M | $9.0B | ||
| Q2 25 | $172.4M | $8.8B | ||
| Q1 25 | $593.6M | $8.6B | ||
| Q4 24 | $825.5M | $5.9B | ||
| Q3 24 | $881.4M | $5.9B | ||
| Q2 24 | $763.6M | $5.7B |
| Q1 26 | — | $68.0B | ||
| Q4 25 | $2.0B | $67.2B | ||
| Q3 25 | $1.8B | $66.0B | ||
| Q2 25 | $1.6B | $65.9B | ||
| Q1 25 | $1.9B | $65.1B | ||
| Q4 24 | $2.1B | $46.4B | ||
| Q3 24 | $2.1B | $46.1B | ||
| Q2 24 | $1.9B | $45.5B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $192.7M | — |
| Free Cash FlowOCF − Capex | $188.1M | — |
| FCF MarginFCF / Revenue | 26.6% | — |
| Capex IntensityCapex / Revenue | 0.6% | — |
| Cash ConversionOCF / Net Profit | 1.43× | — |
| TTM Free Cash FlowTrailing 4 quarters | $681.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $192.7M | $232.1M | ||
| Q3 25 | $246.2M | $122.4M | ||
| Q2 25 | $148.5M | $72.6M | ||
| Q1 25 | $125.8M | $-126.3M | ||
| Q4 24 | $190.7M | $354.3M | ||
| Q3 24 | $149.1M | $-246.8M | ||
| Q2 24 | $116.4M | $126.8M |
| Q1 26 | — | — | ||
| Q4 25 | $188.1M | $215.5M | ||
| Q3 25 | $235.5M | $101.7M | ||
| Q2 25 | $142.4M | $52.5M | ||
| Q1 25 | $115.8M | $-139.1M | ||
| Q4 24 | $183.0M | $340.9M | ||
| Q3 24 | $138.5M | $-254.2M | ||
| Q2 24 | $103.5M | $117.3M |
| Q1 26 | — | — | ||
| Q4 25 | 26.6% | 37.1% | ||
| Q3 25 | 35.7% | 17.0% | ||
| Q2 25 | 23.6% | 9.1% | ||
| Q1 25 | 20.7% | -25.5% | ||
| Q4 24 | 34.1% | 92.2% | ||
| Q3 24 | 26.0% | -72.3% | ||
| Q2 24 | 19.6% | 33.5% |
| Q1 26 | — | — | ||
| Q4 25 | 0.6% | 2.9% | ||
| Q3 25 | 1.6% | 3.5% | ||
| Q2 25 | 1.0% | 3.5% | ||
| Q1 25 | 1.8% | 2.4% | ||
| Q4 24 | 1.4% | 3.6% | ||
| Q3 24 | 2.0% | 2.1% | ||
| Q2 24 | 2.4% | 2.7% |
| Q1 26 | — | — | ||
| Q4 25 | 1.43× | 0.94× | ||
| Q3 25 | 2.22× | 0.50× | ||
| Q2 25 | 1.65× | 0.34× | ||
| Q1 25 | 1.10× | -1.42× | ||
| Q4 24 | 1.63× | 2.46× | ||
| Q3 24 | 1.55× | -1.72× | ||
| Q2 24 | 1.32× | 0.96× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
SSB
| Net Interest Income | $561.6M | 85% |
| Noninterest Income | $100.1M | 15% |
